Opinion: Creating the next wave of antibody therapies requires innovative collaboration
Next-generation broadly neutralizing antibodies (bnAbs) have the potential to transform the fight against global health threats like HIV, malaria, and Ebola. The commercialization of these innovative antibody therapies could save millions of lives annually. But turning promise into reality requires foresight and commitment.
Broadly neutralizing antibodies are a type of protein that can recognize and neutralize a wide range of pathogens, including multiple strains of viruses such as HIV. This versatility makes them highly valuable in medicine, promising effective treatments and preventive measures against infectious diseases. New discoveries are improving the potency and durability of antibodies in general.
